A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy

Neurology. 2003 Aug 26;61(4):528-30. doi: 10.1212/01.wnl.0000079460.21925.d3.

Abstract

Adrenomyeloneuropathy is a peroxisomal disorder that causes demyelination, with no proven therapy. Oral modified cobratoxin was assessed in a double-blind, randomized, crossover study of eight patients. Treatment was well tolerated. There were no significant improvements with therapy. The authors do not confirm previous anecdotal reports of dramatic improvement with modified cobratoxin.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenoleukodystrophy / drug therapy*
  • Adult
  • Aged
  • Cobra Neurotoxin Proteins / therapeutic use*
  • Double-Blind Method
  • Evoked Potentials
  • Female
  • Humans
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Treatment Failure

Substances

  • Cobra Neurotoxin Proteins